Related Experiment Video
Updated: Jun 8, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.2K
CD38 as theranostic target in oncology
Valentina Bocuzzi1,2, Jessica Bridoux3, Michelle Pirotte4
1Laboratory of Hematology, GIGA I3, University of Liège, Liège, Belgium.
Journal of Translational Medicine
|November 5, 2024
Summary
Targeting CD38, a protein overexpressed in blood cancers, is crucial for treatment. Single domain antibodies (sdAbs) offer a new theranostic approach for CD38-expressing malignancies, combining diagnosis and therapy.
Area of Science:
- Oncology
- Immunology
- Nuclear Medicine
Background:
- CD38 is a transmembrane glycoprotein overexpressed in hematological malignancies like leukemia and multiple myeloma (MM).
- It plays a key role in disease progression via ADP-ribosyl cyclase and cADPR-hydrolase activities.
- Current anti-CD38 monoclonal antibodies (mAbs) show efficacy but face resistance, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review the role of CD38 as an oncology target.
- To explore single domain antibodies (sdAbs) as innovative theranostic agents for CD38-expressing cancers.
Main Methods:
- Review of current literature on CD38 targeting in oncology.
- Discussion of diagnostic (PET/SPECT) and therapeutic (alpha/beta emitting radionuclides) radioligand therapy (RLT) approaches.
- Characterization of CD38-specific sdAbs and their engineered constructs for theranostic applications.
Main Results:
- CD38 targeting is a validated strategy in hematological malignancies and shows potential in solid tumors.
- Anti-CD38 mAbs like daratumumab have improved MM treatment outcomes.
- Single domain antibodies (sdAbs) offer advantages in size, stability, and epitope recognition for theranostic development.
Conclusions:
- CD38 remains a significant therapeutic target in oncology.
- Single domain antibodies (sdAbs) represent a promising new generation of theranostic agents for CD38-expressing malignancies.
- Engineered sdAbs provide enhanced tumor targeting and potential for combined diagnostic and therapeutic applications.
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K